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Abstract 
Background: Double-blind, placebo-controlled food challenge (DBPCFC) is considered the gold standard for food 
allergy diagnosis. However, this test is rarely performed routinely in clinical practice because of various practical issues, 
e.g. the lack of a standardized matrix preparation. The aim of this study was to develop and validate a convenient 
DBPCFC matrix, that can easily be implemented in daily clinical practice. The focus of this study was the blinding of 
hazelnuts, whereby the hazelnuts retained as much as possible their allergenicity and could be mixed homogenously 
in low-doses to the matrices.
Methods: A basophil-activation test (BAT), microbial tests and an LC-MS/MS test were performed to assess respec-
tively the allergenicity of the used hazelnuts, the microbial stability of the novel developed matrices and the homo-
geneity of the hazelnuts in the matrices. A sensory test was conducted to validate the blinding of the hazelnuts in the 
matrices. A pilot DBPCFC study included eight patients as proof of concept.
Results: The BAT-test gave the first insights concerning the retained allergenicity of the hazelnuts. The microbial 
safety could be assured after 12 months of storage. Sufficient masking was assessed by several sensory tests. Homo-
geneous hazelnut distribution could be achieved for the different hazelnut concentrations. The DBPCFC’s results 
showed diverse allergic responders (from no reactions to distinct objective symptoms).
Conclusion: A novel stable and validated DBPCFC matrix using raw hazelnuts has been developed that allows easy 
preparation in a standardized way for convenient use in daily clinical practice.
Trial registration EC Project number: EC/2015/0852; Date of registration: 13 Oct 2015; End date: 01 Feb 2017
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matrix
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Background
The double-blind, placebo-controlled food challenge 
(DBPCFC) is considered the gold standard for food 
allergy diagnosis. This is however not common practice 
in the daily clinical setting due to several limitations, 
such as the lack of standardized preparation of the matri-
ces [1]. One of the limiting factors of the DBPCFC is that 
the clinical staff must be able to prepare the matrices by 
themselves, so too labor-intensive preparations (e.g. bak-
ing, etc.) are not likely to be used in the routine.
However, from the clinical perspective, this test is use-
ful to e.g. exclude/confirm a possible food allergy when 
other in vivo/in vitro tests are producing contradictory or 
inconclusive results, evaluate if patients have outgrown 
their allergy and to assess the severity of their reactions. 
For scientific reasons, it can be used to estimate the global 
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prevalence of relevant food allergies, to assess the predic-
tive value of other diagnostic methods and to determine 
specific threshold levels. However, proper validation of 
these matrices has only been performed in limited stud-
ies [2–5]. Further, low allergen dose matrices are needed 
to determine e.g. the minimum eliciting doses (MED’s) of 
the patients and to include safely severe allergic patients 
in this test [6]. As reported in 2014 by the Voluntary Inci-
dental Trace Allergen Labelling 2.0 (VITAL) initiative, 
the MED in 1% of the hazelnut allergic population  (ED0.1) 
is estimated to be 0.1 mg hazelnut proteins [6]. However, 
limited studies have yet been conducted to develop lower 
dose vehicles whereby the homogeneity was determined.
For hazelnuts, as far as we know, only a low-level 
matrix was developed using defatted hazelnuts (start-
ing with 3 µg hazelnut proteins) [2]. However, defatting 
removes oil-body associated allergens which can also 
provoke severe allergic symptoms [7]. The high-fat con-
tent of hazelnuts (±  61%  w/w) however makes homog-
enization and hence masking of the non-defatted nuts 
difficult.
This project focused on the development and valida-
tion of a novel, easy-to-use DBPCFC matrix for raw 
hazelnuts at low-level, which can be used in a standard-
ized way in daily clinical practice and by multiple centers 
to allow comparison of test results. This study reports to 
our knowledge, the first validated matrix containing low 
doses of raw, non-defatted hazelnuts and no other major 
allergenic ingredients listed in the Regulation (EU) No. 
1169/2011.
Methods
Preparation of the DBPCFC matrices
We developed a powder mix that results in a cold choco-
late dessert after the addition of water. The ingredients 
are listed in Table 1. Blanched raw hazelnuts were ground 
in a RETSCH ZM200 mill (RETSCH, Düsseldorf, Ger-
many) with a 0.75 mm sieve and afterward rolled with the 
Exakt 3-wals 80E (Exakt Technologies, Oklahoma, US) at 
350  rotations/min. The protein content was determined 
using Kjeldahl analysis (according to ISO8968-2, conver-
sion factor = 5.18). The rolled hazelnuts were packaged 
under vacuum conditions and stored in the dark at ambi-
ent temperatures (20 °C).
The DBPCFC series were freshly prepared the day 
itself (± 2–4 h prior start of the challenge) (Table 2). For 
the verum vehicles first, a dilution series was prepared 
with suspended hazelnuts in lukewarm water (±  30  °C) 
(Table  2). Each dilution was shaken vigorously until the 
hazelnuts were fully suspended prior preparing the sub-
sequent dilution. Each dilution (65 g) was added per por-
tion of powder mix II (=  40.2  g for verum series 5–9; 
see Table 1) or powder mix I (= 35.0 g for verum series 
1–4; see Table  1). To prepare the placebo series, 65  mg 
lukewarm water was added per portion of powder mix I. 
All the samples were shaken vigorously and set in at 4 °C 
for at least 10 min. Of these preparations, the respective 
Table 1 Ingredients used for the DBPCFC matrix preparation
a No allergens were mentioned on the product information sheet
b Has precautionary labeling on the product information for gluten, eggs, lupine, milk (incl. lactose), soy
c Explicitly mentioned that it contains no allergens
d No allergens were mentioned on the product information sheet, labeled as gluten-free
e Is an amino acid-based formula for babies with a severe cow’s milk protein allergy or with multiple food allergies, it’s an extensively hydrolyzed formula by breaking 
down completely the present proteins in amino acids
Added ingredients Brand Powder mix I (g/portion) Powder mix II (g/portion)
Vanilla  sugara Imperial 10.00 11.00
Brown  sugara Candico 2.50 4.10
Steviaa Pure Via 2.50 2.40
Cacao 100%a Callebaut 8.20 10.70
Cold thickener (Quelli)b Dawn 2.30 1.25
Sunflower Lecithin Sun 400  organicc Lecico 0.30 0.30
Vanilla  aromac Dawn 0.50 0.40
Lemon  extractd LorAnn Super-Strength Flavor 0.06 0.09
Cocos  extractd LorAnn Super-Strength Flavor 0.10 0.17
Speculaas  spicesc J. S. Polak 0.28 0.53
Rice flakes  Vanillea Olvarit 2.80 2.80
Nutramigen  AAe Mead Johnson 5.50 6.50
Total 35.04 40.24
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portion sizes were served as listed in Table  2. Similar 
portion sizes were served in the placebo series as in the 
verum series.
Assessment of microbial stability
To assess the microbial stability of the materials used, the 
 aw-values and microbial constitution of both the powder 
mixes and the rolled hazelnuts were determined. The 
water activity  (aw) was determined using the Benchtop 
Water Activity Meter (Pullman, WA, USA). Enumera-
tions of Escherichia coli (AFNOR BRD-07/01-07/93 
method), Bacillus cereus (ISO 7932) and detection of 
Salmonella (ISO 6579) were performed in the ISO 17025 
accredited lab for food microbiology at the Belgian 
National Reference Lab at Research Institute for Agricul-
ture, Fisheries and Food (ILVO, Melle, Belgium).
Assessment of hazelnut allergenicity
To gain the first insights concerning the preserved aller-
genicity of the blanched rolled hazelnuts, a basophil acti-
vation test (=  BAT) was performed with three selected 
hazelnut allergic patients having the following allergic reac-
tions: oral allergy syndrome (= OAS), a late onset of mild 
urticaria and a severe systemic reaction. Details of the pro-
tocol are described in the Additional file 1: BAT protocol.
Assessment of hazelnut homogeneity
LC-MS analysis was performed to confirm the absence 
of hazelnuts in the powder mixes and to confirm homog-
enous distribution of the hazelnuts in the different verum 
concentrations. Two prepared verum series were sam-
pled and analyzed over two separate time periods. Details 
of the protocol are described in the Additional file  1: 
LC-MS/MS protocol.
Sensory testing
Sensory tests were performed in two main phases to 
evaluate the masking of the hazelnuts (panelists were 
all >  20  years). Panelists with food allergies were not 
included in this test. In phase Ia and Ib, the tests were 
performed in the same sensory evaluation booths, by 30 
and 31 panelists respectively, who were used to perform 
sensory tests. A combination of verum samples contain-
ing the highest hazelnut concentrations and placebo’s (3 
and 2 samples per panelist in phase Ia and Ib, respec-
tively) were given sequentially in different orders. After 
phase Ia, the test was repeated after minor adjustments 
of the matrices. Between each sample, water and crack-
ers were given. After every tasting, they had to answer if 
the dessert contained hazelnuts or not, and if yes, by tast-
ing or smelling. In phase II, the same test was performed 
as in phase Ib, with a consumer’s panel (91 panelists). All 
the tests were analyzed using the  Chi2-test with 95% CI. 
When there was statistically no difference between the 
answers of the verum and placebo samples, the hazelnuts 
were considered sufficient blinded.
DBPCFC pilot study
To validate the usability of the matrices in practice, eight 
DBPCFC’s were performed with patients having a mild 
hazelnut allergy as proof of concept. For patient details, 
see Additional file  1: Table S2. The study was approved 
by the Ethical Committee of the University Hospital (UH) 
Ghent, and all the patients signed an informed consent 
prior to the start of the test. Details of the protocol are 
described in the Additional file 1: DBPCFC protocol.
Results
The rolled hazelnuts (protein content: 14.5% w/w) could 
be added to the matrices homogenously without leaving 
visible particulates.
The BAT assays resulted in different half maximal effec-
tive concentration values  (EC50) for the different patients. 
For patients A, B and C the following EC50 values were 
recorded, respectively: 0.34 and 1.6 µg/mL and 0.32 ng/
mL hazelnut proteins (see in the Additional file 1: Figure 
S1). Blood taken from a non-allergic donor gave no acti-
vation of the basophils.
The water activity  (aw) of the powder mix and rolled 
hazelnuts were respectively 0.486 and 0.477. The micro-
bial enumerations were for E. coli <  10.0  CFU/g, Sal-
monella sp. 0/25 g and Bacillus cereus < 10.0 CFU/g for 
all the analyzed matrices, even after 1 year of storage at 
ambient temperatures (20 °C) in the dark.
In addition, no hazelnuts could be detected in the 
powder mixes after the sensory tests. In Phase Ia (in the 
sensory lab of ILVO), no significant difference existed 
between the placebo and verum group (P =  0.290). No 
significant differences were found in smell nor taste 
between the verum and placebo samples in the group 
of panelists who detected hazelnuts (resp. P  =  0.286 
and 0.102). In phase Ib (in the same sensory lab), 48% 
(whereof 40% guessed) of the panel answered correctly 
for the verum samples and 29% (whereof 44% guessed) 
thought hazelnuts were present in the placebo matrices. 
No significant difference was found between the placebo 
and verum group (P = 0.096). Also for smell and taste, no 
difference was seen (resp. P =  0.354 and 0.208). Of the 
consumer’s panel, 30% (whereof 26% guessed) and 35% 
(whereof 30% guessed) detected hazelnut in the verum 
and placebo samples respectively, so no significant dif-
ference was shown (P = 0.263). Also for smell and taste, 
no difference was seen (P = 0.581 and 0.154). For more 
details regarding the results of the sensorial tests, we 
refer to Additional file 1: Table S1.
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From the LC-MS/MS analysis, a linearity of  R2 = 0.999 
was obtained after analyzing the different verum series 
in duplicate, confirming the expected hazelnut pres-
ence (see Additional file 1: Figure S2). No hazelnuts were 
detected in the blanc powder mixes.
The DBPCFC outcomes are summarized in Table 3. 
During the pilot study, patients 1, 3 and 5 experi-
enced very mild and subjective allergic symptoms at 
the highest hazelnut dose. Only patients 2 and 4 had 
distinct objective signs when performing the test. 
Patient 6 had both for placebo and verum subjective 
complaints, with similar symptoms of OAS. Patients 
8 and 9 experienced no allergic reaction during the 
test. When results were negative (patients 8 and 9) 
or questionable (patients 1, 3 and 5), open provoca-
tion tests were done which were all positive. However, 
these reactions were very mild (for patients 3 and 5 
e.g. only a mild tingling on the lips or a raw feeling 
in the throat was experienced after consuming 5 raw 
hazelnuts).
Table 3 DBPCFC results of the eight patients
a Symptoms and signs were assessed according to the standardized clinical parameters checklist described in the work of Sampson et al. [1]. OAS symptoms/signs 
were reported extra
+, positive test because of distinct objective signs during the challenge; +/−, results are uncertain because of subjective symptoms during the challenge; −, no 
reactions were observed during the challenge
Results challenge
Patient no. Dose Signs and  symptomsa Test outcome
1 Verum 3–9 Very mild tingling on the lips +/−; Only mild OAS symptoms; open provocation 
test needed
Placebo 1–9 – −
Open provocation: ½ hazelnut Mild tingling on tongue and lips +/−
2 Verum 4–5 Tingling of the lips, Pruritus
Mild urticaria/angioedema of the lips (11 min after 
verum 4)
+; Test is stopped after dose 5 because of inconven-
ient allergic complaints
Placebo 1–9 – −
3 Verum 9 Very mild tingling on the lips +/−; Only mild OAS symptoms; Open provocation 
test needed
Placebo 1–9 – −
Open provocation: 5 hazel-
nuts
Raw feeling in the throat +
4 Verum 2–7
Verum 8–9
Pruritus, urticaria lesion in the neck
Sneezing, itchy nose
+
Placebo 1–9 – −
5 Verum 9 Very mild tingling of the lips +/−; Only mild OAS symptoms; Open provocation 
test needed
Placebo 1–9 – −
Open provocation: 5 hazel-
nuts
Raw feeling in the throat +
6 Verum 1–9 Very mild tingling of the lips Verum and placebo challenges gave both mild OAS 
symptoms. This could be due to the anxiety of the 
patient during the challenges. Open provocation 
test is needed
Verum 9 Gastrointestinal: Nausea
Placebo 1–9 Very mild tingling of the lips
Placebo 9 Gastrointestinal: Nausea
Open provocation: ½ hazelnut Mild tingling of throat and tongue +/−
7 Verum 1–9 – –
Placebo 1–9 – –
Open provocation: ½ hazelnut Mild tingling of throat and tongue +/−
8 Verum 1–9
Placebo 1–9
Open provocation: ½ hazelnut Urticaria: discrete blister lower lip +/−
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Discussion
The main purpose of this work was the development of a 
DBPCFC matrix for hazelnuts which had to fulfill several 
criteria like the sufficient masking of the hazelnuts and 
maintaining as much as possible the allergenicity. Further, 
easy logistics and preparation, long stability and suffi-
cient palatability of the matrices are required. To include 
as much as possible different food allergic patients in this 
test, no other major allergenic food allergens listed in the 
Regulation (EU) No. 1169/2011 were used as ingredients 
during the recipe development of these matrices.
In this work, blanched hazelnuts (protein content: 
14.5% w/w) were used because the dark testa is diffi-
cult to mask, both visually and in taste. For this reason, 
these were also used in other DBPCFC studies [4]. The 
nuts were kept at 100 °C for 8 min to remove this testa. 
Reduced allergenicity of the heat-labile hazelnut Cor 
a 1 and 2 allergens was only noticed at > 140  °C [8] but 
not much is known concerning the impact of blanch-
ing hazelnuts. Minor or no differences in allergenicity 
were seen in other blanched tree nuts, however [8]. For 
the three patients tested, basophil activation was shown, 
even for the least sensitive patient, presuming a retained 
allergenic potential of the blanched hazelnuts. However, 
further research should examine the significant impact of 
blanching on the hazelnut allergenicity.
To limit the potential impact of further processing on 
the hazelnut allergenicity, a cold matrix preparation was 
chosen. The fat content of the verum and placebo matri-
ces were kept at < 25% of the total energy (resp. 13 and 
19% of the total energy) so delayed absorption due to a 
high-fat content will be minimized [4]. The rolled hazel-
nuts could be mixed in the powder without leaving vis-
ible particulates.
The stability of the preparations was assessed by deter-
mining the  aw-values and the microbial contamination. 
The  aw-value can predict the growth of bacteria, yeast, and 
molds over time. For the hazelnuts and powder mix, these 
were low enough to inhibit bacterial and mold growth 
(resp.  aw ≥ 0.91 and 0.8). In addition, no relevant microbial 
spoilage was observed by organisms typically associated 
with confectionery-related food products with low water 
activity, like hazelnuts, after 1 year of storage at room tem-
perature (20  °C), so an easy logistics of both the powder 
mixes and rolled hazelnuts can be guaranteed [9–11].
Instead of the most frequently applied triangle test 
[12], which focuses on differences between matrices 
whatever the attribution of difference is, the sensory 
test performed in this study was specifically adapted for 
its purpose [4], which was comparable with earlier per-
formed sensory tests for DBPCFC matrix validation [3–
5], whereby one placebo and verum sample were offered. 
In this test, the samples were offered sequentially instead 
of simultaneously, as done in the study of González-Man-
cebo et al. [5]. When small differences are not linked to the 
presence of the allergenic ingredient, the samples can be 
offered sequentially [5]. This represents how a DBPCFC is 
carried out in clinical practice, whereby the matrices will 
be given on separate days. We can conclude that consid-
ering the followed procedure and the results obtained, 
the hazelnuts were successfully blinded in our developed 
matrices. Consequently, the newly developed DBPCFC 
matrices will minimize the psychological placebo-effects 
for the patients and the healthcare professionals.
As a proof of concept, DBPCFC’s with eight patients 
were conducted in the clinical setting. The dosage sched-
ule was a combination of semi-logarithmic and logarith-
mic increases, as performed in an earlier DBPCFC study 
in 2012 for hazelnuts [2], whereby similar protein por-
tions were administered. This schedule was performed 
to achieve the top dose with acceptable increments in an 
acceptable period when starting with low-level protein 
portions.
The most sensitive patient had already subjective 
symptoms after the first dose and developed objective 
signs after the second hazelnut dose (corresponding to 5 
and 54 µg of hazelnut proteins, respectively). These find-
ings were comparable with those found earlier whereby 
30 µg of hazelnut proteins was the lowest eliciting dose 
[2]. However, other factors, which were not included in 
this study, like exercise, alcohol consumption, asthma 
and anxiety might exacerbate the allergic reactions, so 
follow-up studies are necessary [13]. Further, the chal-
lenges were performed during September–November, 
and pollen-related food allergies can be worse during 
and just after pollen season (for birch pollen: ±  mid-
dle of March until the middle of May) [14]. Different 
explanations could reason the absence of allergic symp-
toms for the two negative responders, like possible 
matrix/processing effects, too low doses of hazelnuts 
and the removing of the testa. Open provocation tests 
are therefore of utmost importance at the end of the 
test. However, psychological effects cannot be excluded 
then. Since patients with anaphylaxis and children were 
excluded from this DBPCFC study, further research 
should be conducted including younger and more severe 
allergic patients. During the challenges of this work, the 
patients nor health care professionals could discover the 
verum series. Most of the patients found the deserts easy 
to consume.
Conclusion
To conclude, this study reports the production and vali-
dation of a novel DBPCFC matrix for raw hazelnuts 
at low doses,  in a format that allows easy logistics and 
implementation in the common clinical setting.
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series (Hazelnut peptide (R)INTVNSNTLPVLR(W) m/z 721.3 → 1013.7). Top: 
Standard curve of the verum dilution series. Down: Chromatographic peak 
of hazelnut peptide.
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